GlobeNewswire Inc | Oct 26, 2021 02:00AM EDT

October 26, 2021

LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on Tuesday, November 9, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 7220560:

-- +1-888-317-6003 for callers in the United States -- +1-412-317-6061 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Companys website, www.veronapharma.com, and the audio replay will be available for 90 days.

For further information please contact:

US Tel: +1-833-417-0262Verona Pharma plc UK Tel: +44 (0)203 283 4200Victoria Stewart, Director of Investor Relations and info@veronapharma.comCommunications Argot Partners Tel: +1-212-600-1902(US Investor Enquiries) verona@argotpartners.comKimberly Minarovich / Michael Barron Optimum Strategic Communications Tel: +44 (0)203 950 9144(International Media and European Investor Enquiries) verona@optimumcomms.comMary Clark / Stella Lempidaki / Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharmas product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.